Rituximab in the treatment of inflammatory myopathies: a review

被引：83

作者：

Fasano, Serena ^{[1
]}

Gordon, Patrick ^{[2
]}

Hajji, Raouf ^{[3
]}

Loyo, Esthela ^{[4
]}

Isenberg, David A. ^{[5
]}

机构：

[1] Univ Naples 2, Dept Clin & Expt Med, Rheumatol Unit, Naples, Italy

[2] Kings Coll Hosp London, Ctr Rheumatol, Dept Med, London, England

[3] Sidi Bouzid Hosp, Fac Sousse, Dept Internal Med, Ibn Aljazzar Med, Sidi Bouzid, Tunisia

[4] Serv Reumatol Inmunol Clin HRUJMCB, Jefe Serv, Santiago, Dominican Rep

[5] UCL, Dept Med, Ctr Rheumatol, London, England

来源：

RHEUMATOLOGY | 2017年 / 56卷 / 01期

关键词：

inflammatory myopathies; dermatomyositis; polymyositis; anti-synthetase syndrome; rituximab; INTERSTITIAL LUNG-DISEASE; ANTI-SYNTHETASE SYNDROME; CELL DEPLETION THERAPY; JUVENILE DERMATOMYOSITIS; REFRACTORY POLYMYOSITIS; RESPIRATORY-FAILURE; MYOSITIS; EFFICACY; PATIENT; ADULT;

D O I：

10.1093/rheumatology/kew146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.

引用

页码：26 / 36

页数：11

共 50 条

[31] Review: An update on inflammatory and autoimmune myopathies
Dalakas, M. C.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2011, 37 (03) : 226 - 242
[32] Idiopathic inflammatory myopathies. A review
Acosta, Ignacio
Manuel Matamala, Jose
Jara, Paula
Pino, Francisca
Gallardo, Alejandra
Verdugo, Renato
REVISTA MEDICA DE CHILE, 2019, 147 (03) : 342 - 355
[33] Idiopathic inflammatory myopathies-a review
Jones, Jonathan
Wortmann, Robert
CLINICAL RHEUMATOLOGY, 2015, 34 (05) : 839 - 844
[34] Rituximab in the Management of Idiopathic Inflammatory Myopathies complicated by Interstitial Lung Disease
Riddell, P.
O'Mahony, A. M.
Murphy, G.
Ryan, J. G.
Harney, S.
Tormey, V.
Henry, M. T.
IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S439 - S440
[35] Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies
Janardana, Ramya
Amin, S. N.
Rajasekhar, Liza
Pinto, Benzeeta
Kodishala, Chanakya
Selvam, Sumithra
Shobha, Vineeta
RHEUMATOLOGY, 2023, 62 (03) : 1243 - 1247
[36] RITUXIMAB IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
Khelkovskaya-Sergeeva, A. N.
Antelava, O. A.
Olyunin, Y. A.
Tarasova, G. M.
Lopatina, N. E.
Palshina, S. E.
Sazhina, E. G.
Nikonorova, N. O.
Koneva, O. A.
Alexandrovna, E. N.
Nasonov, E. L.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 741 - 742
[37] Rituximab in the Management of Idiopathic Inflammatory Myopathies complicated by Interstitial Lung Disease
Riddell, P.
O'Mahony, A. M.
Murphy, G.
Ryan, J. G.
Harney, S.
Tormey, V.
Henry, M. T.
IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S439 - S440
[38] Pathogenesis, classification and treatment of inflammatory myopathies
Zong, Mei
Lundberg, Ingrid E.
NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (05) : 297 - 306
[39] Advances in the immunobiology and treatment of inflammatory myopathies
Dalakas M.C.
Current Rheumatology Reports, 2007, 9 (4) : 291 - 297
[40] TREATMENT TRAJECTORIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES
Wipfler, K.
Sbarigia, U.
Zazzetti, F.
Sheahan, A.
Lin, I.
Alemao, E.
Michaud, K.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 956 - 957

← 1 2 3 4 5 →